HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Review: PCSK9 emerges as a regulator of cardiometabolic aging in heart and liver

Louis Nervegna · Jan 31, 2024 · ♥ 15 reactions · 9 comments · original Facebook post
PCSK9, ezetimibe & newer drugsAging & longevity
AI summary & key facts

Louis suggests PCSK9 inhibitor drugs may be treating aging itself in the cardiovascular system and liver, sharing a February 2024 GeroScience review. The review describes PCSK9 as an emerging regulator of cardiometabolic aging, with links between liver aging, lipid metabolism and cardiovascular health, drawing on work from the Pacher laboratory. The claim about drugs treating aging is speculative.

These new PCSK9 inhibitor drugs may actually be treating the AGING process itself, at least in the cardiovascular system and liver.

#pcsk9HD #agingHD #longevityHD

Research cited

PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarker

February 2024

Paper · GeroScience · 2023PCSK9: an emerging player in cardiometabolic aging and its potential as a therapeutic target and biomarkerProprotein convertase subtilisin/kexin type 9 (PCSK9), renowned for its pivotal role in low-density lipoprotein (LDL) regulation, has emerged as a compelling regulator of cardiometabolic aging. Beyond its well-established involvement in cholesterol metabolism, PCSK9’s multifaceted influence on the aging processes of the cardiovascular and metabolic systems is garnering increasing attention. This review delves into…doi.org

Proprotein convertase subtilisin/kexin type 9 (PCSK9), renowned for its pivotal role in low-density lipoprotein (LDL) regulation, has emerged as a compelling regulator of cardiometabolic aging. Beyond its well-established involvement in cholesterol metabolism, PCSK9’s multifaceted influence on the aging processes of the cardiovascular and metabolic systems is garnering increasing attention.

This review delves into the evolving landscape of PCSK9 in the context of cardiometabolic aging, offering fresh insights into its potential implications. Drawing inspiration from pioneering research conducted by the Pacher laboratory (Arif et al., Geroscience, 2023, PMID: 37726433), we delve into the intricate interplay of PCSK9 within the aging heart and liver, shedding light on its newfound significance. Recent studies underscore PCSK9’s pivotal role in liver aging, suggesting intriguing connections between hepatic aging, lipid metabolism, and cardiovascular health. Additionally, we explore the therapeutic potential of PCSK9 as both a target and a biomarker, within the context of age-related cardiovascular disease.

No photo description available.
← newer: Cardiologist Joel Kahn puts nearly all his patients on citruolder: Harvard: 1-2 weekly servings of fatty fish linked to 36% low →